A Penn surgeon is the first in the Philadelphia region to offer the Resensation treatment.
Carisma Therapeutics wants to be the first to engineer a macrophage, a parasite-eating white blood cell found in humans, to destroy cancer tumors.
B.PHL’s chief planner, Michelle Histand, says the festival will be bigger and better in 2020. Here’s what you can expect to see.
One expert says the the Federal Trade Commission’s complaint is itself enough to kill the proposed deal.
Move over, Siri and Alexa. WellBe is here to take the virtual assistant market to new heights with at-home healthcare support.
Castle Creek Biosciences is developing several treatments that may provide relief for “Butterfly Children” and others living with rare genetic diseases.
Venatorx Pharmaceuticals is leading the race to develop new antibiotics before the next drug-resistant superbug spreads.
With an innovative curriculum, the partnership offers faster paths to careers in the growing sector.
Ocugen has developed a new platform that could help bring greater attention to underserved areas of ophthalmology.
Repisodic has developed a technology solution to help patients and their families make smarter, faster decisions about post-acute care.
With a $100 million investment, MRA Group hopes to turn the suburban research campus into an energy-efficient innovation hub.
The local company is developing solutions that can improve treatment and outcomes for cancer patients.
Einstein Medical Center is one of the first hospitals in the nation to allow visitors to register to vote with kiosks on site.